Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have received a consensus rating of “Moderate Buy” from the fifteen brokerages that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $76.67.

Several equities analysts have weighed in on the company. Oppenheimer increased their target price on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. Wedbush decreased their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. UBS Group lowered their target price on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday. Mizuho lowered their price target on Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating on the stock in a research report on Monday, April 29th. Finally, Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $68.00 to $80.00 in a research note on Monday, February 5th.

Apellis Pharmaceuticals Stock Up 0.5 %

NASDAQ APLS opened at $42.52 on Friday. The stock has a market cap of $5.16 billion, a PE ratio of -12.29 and a beta of 0.97. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75. The firm has a 50-day simple moving average of $53.91 and a 200 day simple moving average of $57.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). The business had revenue of $172.33 million for the quarter, compared to the consensus estimate of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The firm’s quarterly revenue was up 284.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.56) EPS. On average, research analysts forecast that Apellis Pharmaceuticals will post -1.27 EPS for the current year.

Insider Activity at Apellis Pharmaceuticals

In related news, CFO Timothy Eugene Sullivan sold 1,431 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $96,978.87. Following the sale, the chief financial officer now owns 93,338 shares in the company, valued at approximately $6,325,516.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Adam J. Townsend sold 1,148 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $67.77, for a total value of $77,799.96. Following the completion of the transaction, the insider now directly owns 92,453 shares of the company’s stock, valued at $6,265,539.81. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 1,431 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $96,978.87. Following the completion of the transaction, the chief financial officer now owns 93,338 shares of the company’s stock, valued at approximately $6,325,516.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 455,334 shares of company stock valued at $26,511,351. 7.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of APLS. Sippican Capital Advisors lifted its stake in shares of Apellis Pharmaceuticals by 1.1% during the 4th quarter. Sippican Capital Advisors now owns 16,004 shares of the company’s stock valued at $958,000 after buying an additional 170 shares in the last quarter. Treasurer of the State of North Carolina raised its holdings in Apellis Pharmaceuticals by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 43,800 shares of the company’s stock valued at $1,666,000 after acquiring an additional 230 shares during the period. First Horizon Advisors Inc. lifted its position in shares of Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after acquiring an additional 265 shares in the last quarter. Future Financial Wealth Managment LLC purchased a new stake in shares of Apellis Pharmaceuticals during the first quarter worth $29,000. Finally, Arizona State Retirement System grew its position in shares of Apellis Pharmaceuticals by 2.4% in the third quarter. Arizona State Retirement System now owns 23,211 shares of the company’s stock valued at $883,000 after purchasing an additional 541 shares in the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).